Expanding Global Reach Through Strategic Partnerships

Ozon Pharmaceuticals is strengthening its international presence with new agreements to supply pharmaceutical products to Oman and Pakistan. The company finalized these deals in 2025, marking a significant step in its export expansion strategy.

According to the company’s press service, the strongest interest from partners lies in oncology drugs and biotech products, reflecting the growing demand for advanced treatments in both regions. This expansion is part of Ozon’s broader vision to establish itself as a trusted global supplier of innovative medicines.

Beyond Oman and Pakistan, Ozon is actively negotiating with companies in the UAE, Algeria, Morocco, Jordan, Nicaragua, and Syria. These discussions highlight the company’s ambition to diversify its markets and strengthen its role in international healthcare.

In 2025, Ozon successfully supplied medicines under government contracts to Iraq and Yemen, using both existing registrations and special import permits. Commercial shipments also reached Iraq, Belarus, and Turkmenistan, where the company markets Skinoclear (azelaic acid) — the only Russian drug with this active ingredient, available in gel and cream forms for treating acne, rosacea, and hyperpigmentation.

Company executives acknowledge that entering foreign markets requires significant investment in registration procedures and supply chain development. However, they remain confident that the upcoming launch of high‑tech products from Ozon Medica and Mabscale will open new opportunities for growth.

By expanding into Oman and Pakistan, Ozon Pharmaceuticals is not only broadening its global footprint but also contributing to improved access to advanced medicines in regions where demand for oncology and biotech solutions continues to rise.